Investigación oncológica en
Centro de Oncología Helen F. Graham
y el Instituto de Investigación

Investigación sobre el cáncer de mama

Descripción general del programa

The breast cancer research program at the Helen F Graham Cancer Center and Research Institute brings together a multi-disciplinary team of clinicians, scientists, nurses and community educators to promote research aimed at improving breast cancer prevention, diagnosis, treatment and survivorship for women from all racial, cultural and socioeconomic backgrounds. Program members have expertise in medical and surgical oncology, pathology, psychology, medical genetics, cellular signaling, molecular biology, immunology, chemical engineering, nanotechnology, epidemiology, outreach and supportive care.

For more information, call 302-623-4508 or e-mail us.

Para las mujeres con cáncer de mama, un estudio hace posibles mejores estrategias para tratar el dolor a través del ejercicio.

Luchar contra el cáncer de mama agresivo.

Researchers from the Center for Translational Cancer Research uncover effects of TGFß on Inflammatory Breast Cancer cells

Kenneth Van Golen, Ph.D., and Ph.D. student Sangjucta Barkataki uncover the effects of local and radiation enhanced TGFß on the invasive nature of Inflammatory Breast Cancer (IBC) cells in their work at the Center for Translational Cancer Research at Christiana Care. The objective of their research is to first understand how skin metatases occur in IBC and then find a way to block their formation. Thanks to a grant from the IBC Network Foundation and support from Christiana Care and the University of Delaware, Van Golen and Barkataki are moving full-steam ahead with their ground-breaking research.


Establish a breast center of excellence that uses our collective energies to: promote evidence-based breast cancer research, improve lives of breast cancer patients, and, eliminate disparities in breast cancer outcomes for all Delawareans.


To translate research findings to offer access to cutting edge care across all patient populations.


  1. Determine factors that contribute to differences in breast cancer incidence and outcomes across population groups in the state of Delaware.
  2. Improve treatment outcomes and increase participation in translational research by minority communities.
  3. Identify novel biomarkers that may serve as early predictors of cancer risk and recurrence.
  4. Develop new treatments for aggressive breast cancers.
  5. Develop new interventions to reduce side effects of current treatments.
  6. Develop early stage clinical trials that benefit patient populations.


Translational Director, Jennifer Sims-Mourtada, Ph.D.
Clinical Director, Diana Dickson-Witmer, M.D., FACS.
Administrative Director, Pat Swanson, BSN.


Zohra Ali-Khan Catts, MS, LCGC.
Emily Day, Ph.D., University of Delaware.
April Kloxin, Ph.D., University of Delaware.
Nora Katurakes.
Scott Siegel, Ph.D.
Ramya Varadarajan, M.D.
Kenneth van Golen, Ph.D., University of Delaware.

Programa de Investigación sobre el Cáncer
Centro de Oncología e Instituto de Investigación Helen F. Graham

4701 Ogletown-Stanton Road, Newark, DE 19713 indicaciones

Powered by GlobalLink OneLink Software